Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Diabetes
•
Endocrinology
Which patient population would most benefit from inhaled insulin (Afrezza)?
Related Questions
What is your experience with the use of automated insulin delivery systems (such as Control IQ with Tandem insulin pumps) in pregnant patients with diabetes?
Should GLP-1 agonists be weaned in patients who have achieved goal weight loss and glycemic control?
Do you recommend continuous glucose monitoring for patients with Type 2 diabetes who are not on insulin?
Would you consider GLP1 R agonist therapy in a patient with a history of severe gallstone pancreatitis that is now post cholecystectomy?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
Are recurrent UTIs a contraindication to SGLT2i use?
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?
Should short courses of insulin be considered for steroid-induced hyperglycemia in patients with pre-diabetes or mild diabetes well controlled on oral therapy?
